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ABSTRACT 
Background. Atrial fibrillation (AF) ablation outcome is still operator dependent. Ablation 
Index (AI) is a new lesion quality marker that has demonstrated to allow acute durable 
pulmonary vein (PV) isolation followed by a high single-procedure arrhythmia-free survival.  
Objectives. This prospective, multi-center study was designed to evaluate the inter-operator 
reproducibility of acute PV isolation guided by the AI. 
Methods. A total of 490 consecutive patients with paroxysmal (80.4%) and persistent AF 
underwent first time PV encircling and were divided in four study groups according to 
operator preference in choosing the ablation catheter (a contact force (ST) or contact force 
sourrounding flow (STSF) catheter) and the AI setting  (330 at posterior and 450 at anterior 
wall or 380 at posterior and 500 at anterior wall). Radiofrequency was delivered targeting 
interlesion distance ≤ 6 mm. 
Results. Procedure (ST330 129±44 min, ST380 144±44 min, STSF330 120±72 min, 
STSF380 125±73 min, p<0.001) and fluoroscopy time (ST330 542±285 s, ST380 540±416 s, 
STSF330 257±356 s, STSF380 379±454 s, p<0.001) significantly differed among the four 
study groups, whereas the rate of first-pass PV isolation (ST330 90±16 %, ST380 87±19 %, 
STSF330 90±17 %, STSF380 91±15 %, p=0.585) was similar. The difference in the rate of 
first pass isolation was not statistical different (p=0.06) among the 12 operators that 
performed at least 15 procedures. 
Conclusions. Ablation protocol respecting strict criteria for contiguity and quality lesion 
results in high and comparable rate of acute PV isolation among operators performing 
ablation with different catheters, AI settings, procedure and fluoroscopy times. 
 
CONDENSED ABSTRACT 
This prospective, multi-center study was designed to evaluate the inter-operator 
reproducibility of acute pulmonary vein (PV) isolation guided by the AI in 490 patients with 
paroxysmal and persistent atrial fibrillation. Patients were divided in four study groups 
according to operator preference in choosing the ablation catheter (a contact force or contact 
force sourrounding flow catheter) and the AI setting  (330 at posterior wall and 450 at 
anterior wall or AI 380 at posterior wall and 500 at anterior wall). Radiofrequency was 
delivered targeting interlesion distance ≤ 6 mm. Procedure and fluoroscopy time significantly 
differed among the four study groups, whereas the rate of first-pass PV isolation was similar. 
We conclude that an ablation protocol respecting strict criteria for contiguity and quality 
lesion results in high and comparable rate of acute PV isolation among operator performing 
ablation with different catheters, AI settings, procedure and fluoroscopy times. 
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ABBREVIATIONS 
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PV= pulmonary vein 
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INTRODUCTION 
Catheter ablation is a well established therapy in the management of patients with atrial 
fibrillation (AF) after failure of a pharmacological trial or as first-line therapy (1,2). However 
the wide range of success and complication rates among the several operator and centers 
justify the recommendation that ablation should be performed by an electrophysiologist who 
has received appropriate training and who perform the procedure in an experienced centre 
(2). To overcome these limitations and simplify the ablation procedure, several one-shot 
techniques have been developed (3-6). When ablation is performed with a point-by-point 
approach, the operator dependent outcome (7) still remains a limitation of the procedure. 
Recently, the use of a new lesion quality marker, the Ablation Index (AI) (Biosense-Webster, 
Diamond Bar, California) has demonstrated to allow acute durable pulmonary vein (PV) 
isolation followed by a high single-procedure arrhythmia-free survival (8-10). This 
prospective, multi-center study was designed to evaluate the inter-operator reproducibility of 
acute PV isolation guided by the AI. 
METHODS 
The Ablation Index Registry (AIR) (ClinicalTrials.gov Identifier: NCT03277976) is a 
prospective, multi-center, research study designed to evaluate the acute achievement of PV 
isolation with ThermoCool SmartTouch (ST) (Biosense-Webster, Diamond Bar, California) 
or ThermoCool SmartTouch SF (STSF) (Biosense-Webster, Diamond Bar, California) 
catheter using the AI Module. Enrollment started in November 2017 and ended in July 2018. 
The study was approved by local Ethics Committees and complied with the Declaration of 
Helsinki guidelines. Written informed consent was obtained from all patients. 
Study population. We enrolled patients with paroxysmal or persistent AF who underwent 
their first AF ablation. Exclusion criteria were: 1) age < 18; 2) permanent AF (AF was the 
sole rhythm for the last 12 months); 3) AF secondary to a transient or correctable 
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abnormality, including electrolyte imbalance, trauma, recent surgery, infection, toxic 
ingestion, and endocrinopathy; 4) intra-atrial thrombus, tumor, or other abnormality 
precluding catheter insertion; 5) left ventricular ejection fraction < 35%; 6) women of 
childbearing potential who are or might be pregnant; 7) hematological contraindications to 
ionizing radiation exposure; 8) presence of complex congenital heart disease, and cardiac 
surgery within 1 month from enrollment. 
Study protocol. This registry compared different clinical practices. Each operator performed 
AF catheter ablation using its own ablation technique as concerning the ablation catheter (ST 
or STSF) and the AI setting (380 posterior-500 anterior and 330 posterior-450 anterior). 
Therefore the study population was divided in 4 groups: ST 330-450, ST 380-500, STSF 330-
450, and STSF 380-500. No randomization was required neither any deviation from the 
clinical practice of each center and operator.  
End points. Given that the rate of PV isolation with a standard wide antral circumferential 
ablation technique (first pass isolation) is about 70% (8,11), we wanted to test if one of two 
catheters or one of two AI settings could increase the first pass isolation rate of at least 10% 
(from 70% to 80%, 95% CI 75-85%). Patients were divided in 4 groups and enrollment 
stopped when at least 80 patients were enrolled in each group. The primary end point of the 
study was to evaluate which ablation strategy increases the rate of  PV isolation, validated by 
mean of a duodecapolar LASSO (Biosense-Webster, Diamond Bar, California) catheter, after 
first encirclement (first pass isolation), from 70% to 80%. Secondary end points were: a) 
incidence of early PV reconnection 30 minutes after acute PV isolation; b) difference in 
procedural and fluoroscopy time between the two groups; c) incidence of AF recurrence 
during the blanking period (3-months after ablation); d) safety of the ablation procedure.  
Study Procedures. Ablation was usually performed under effective oral anticoagulation. 
Anticoagulation could be withdrawn before admission, so as antiarrhythmic drugs were 
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usually removed before scheduled procedure. Patients in AF or with a CHA2DS2-VASc score 
≥ 1 underwent transesophageal echocardiography within 48 hours prior to the ablation. For 
all other patients transesophageal echocardiography was optional according to center and 
operators’ preference. A pre-acquired computed tomography or magnetic resonance scan was 
used according to operators’ preference. Ablation was carried out under mild or conscious 
sedation or general anesthesia according to operators’ preference. At least 2 femoral vein 
access were obtained and in some patients one subclavian vein. One diagnostic catheter was 
positioned in the coronary sinus. One or two transseptal accesses to the left atrium were 
achieved using a standard approach. Then, the LASSO catheter and the ablation catheter (ST 
or STSF) were placed in the left atrium. Left atrium mapping was performed in sinus rhythm. 
Patients with AF at the beginning of the index procedure underwent electrical cardioversion. 
After left atrium reconstruction the effective PV-left atrium electrical connection was 
checked with LASSO catheter (Figure 1). Radiofrequency pulses were delivered using the 
3.5-mm Thermocool ST or STSF Catheter in power control mode. Radiofrequency power 
was  set between 20 and 35 W depending on different left atrial sites and the catheter tip was 
irrigated by saline at a flow rate of 2 mL/min during mapping and of 8 mL/min and 15 
mL/min used for outputs of less than and greater than 30 W, respectively (12). 
Radiofrequency energy was delivered to produce a wide area circumferential ablation around 
the proximal part of each PV’s ostium or around ipsilateral PVs according to the patient’s 
anatomy or operator’s preference. The lesion around the PV ostium was created by sequential 
point-by-point application of radiofrequency energy. Real-time automated display of RF 
applications (Carto VISITAGTM Module, Biosense Webster) was used with predefined 
settings of respiration adjustment, catheter stability (3 mm for 3 s), minimum contact force (3 
g over minimum 25% of time), with the lesion tag display size of 3 mm, and AI thresholds: 
500 for anterior wall and 380 for posterior wall or 450 for anterior wall and 330 for posterior 
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wall. In case of dislocation, a new RF application reaching the AI target was applied. 
Maximal inter lesion distance between 2 neighboring lesions was ≤ 6 mm (9,13). Upon 
completion of circumferential ablation a circular mapping LASSO catheter was used to 
confirm PV isolation (first pass isolation) (Figure 2). In the absence of isolation after 
completing the circle, touch-up ablation was delivered until PV isolation. Resumption of left 
atrium to PV conduction was evaluated for 30 minutes after ablation. In case of reconnection 
PVs were newly isolated targeting the residual electrical breakthroughs.  
All patients underwent a post-procedural ECG and, optional, an echocardiogram to exclude 
pericardial effusion or other acute complications. 
Follow-up. After ablation, patients underwent regular follow-up assessments (scheduled at 3, 
6, and 12 months) including a detailed history, physical examination, 12-lead standard 
electrocardiography, and 24-h Holter monitoring. 
Statistical analysis. All continuous data were expressed in terms of the mean and the 
standard deviation of the mean, the categorical data were expressed as frequency and 
percentages. The Kolmogorov Smirnov test was performed to test normality of continuous 
variables. The Levene test was performed to assess homoscedasticity of the studied groups. 
The ANOVA test was performed to assess the between groups differences of continuous, 
normally distributed and homoscedastic data, the Mann Whitney test was used otherwise. The 
ANOVA test followed by the Scheffè post hoc pairwise comparison was also used to assess 
the differences of continuous, normally distributed and homoscedastic data, among the 
groups, the Kruskal Wallis test followed by the Mann Whitney test with the Bonferroni 
correction for multiple comparison was used otherwise. Fisher Chi square test was performed 
to investigate the relationships between dichotomous variables. Pearson Chi square test 
evaluated by Monte Carlo Methods for small samples was performed to investigate the 
relationships between grouping variables. For all tests p<0.05 was considered significant. 
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All statistical analysis was performed using SPSS v.19.0 (IBM Corp., Armonk, NY, USA) 
 
RESULTS 
Study population. A total of 490 patients were enrolled in the study: in 96 patients in ST 
330-450 Group, 81 in ST 380-500 Group, 162 in STSF 330-450 Group, and 151 in STSF 
380-500 Group. The clinical characteristics of the study population are summarized in the 
Table 1.  
Procedural data. At the beginning of the procedure 13.3% (13,5% in ST 330-450 Group, 
17.3% in ST 380-500 Group, 13.6% in STSF 330-450 Group, and 10.6% in STSF 380-500 
Group, p=0.539) of patients were in AF and underwent electrical cardioversion. In the Table 
2 are summarized the main procedural data. Although the incidence of a PV common ostium, 
the mean procedural time, fluoroscopy time, and contact force were different among the four 
study groups, the rate of first pass isolation was similar. Also the mean impedance drop did 
not differ among the four study groups. Saline infusion was lower when catheter ablation was 
performed using a STSF catheter. Resumption of left atrium to PV conduction 30 minutes 
after ablation was observed in 5.6% (2.5% in ST 330-450 Group, 5.5% in ST 380-500 Group, 
5.5% in STSF 330-450 Group, and 7.8% in STSF 380-500 Group, p<0.001) of PVs.   
Reproducibility of first pass pulmonary vein isolation. A total of 44 operators, in 25 
centers, performed the 490 ablation procedures. Figure 3 shows the distribution of first pass 
PV isolation among the 12 operators that performed at least 15 ablation procedures. All 
operators reached a rate of first pass PV isolation ≥ 84%. The difference in the rate of first 
pass isolation was not statistical different (p=0.06) among these 12 operators. 
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Complications. A complication (3 pericardial effusions, 2 transient phrenic nerve pulsy, 1 
cardiac thamponade, 1 pneumonia, 1 other) was observed in 8 (1,6%) patients without any 
difference among the four study groups (p=0.55). 
 
DISCUSSION 
Main findings. This study, evaluating the inter-operator reproducibility of acute PV 
isolation, shows that an ablation protocol respecting strict criteria for contiguity and quality 
lesion results in high and comparable rate of acute PV isolation among operator with different 
skill performing ablation with different catheters, AI settings, procedure and fluoroscopy 
times. The difference in the patients’ clinical characteristics and left atrium volume and 
morphology did not impact the rate of PV isolation. These results were obtained without 
compromising safety. When a lower AI value was chosen it did not impact the safety and the 
acute efficacy of the ablation.  
Reproducibility of AF ablation. The HRS/EHRA/ECAS expert consensus 
statement on catheter and surgical ablation of AF (14) reports that among the unanswered 
questions in AF ablation the need of improving the efficacy and safety of catheter ablation. 
As ablation extends to more and less experienced operators, the statistical occurrence of 
complications will increase. We need newer techniques to minimize complications and 
institute standards for operators to improve the reproducibility of ablation results and safety 
profiles at a variety of centers worldwide. Our study seems to give some answer to this query. 
We did not have measures of centers volume or operators’ experience, nevertheless the 
procedure and fluoroscopy time were significantly different among the four study groups. 
Previous studies have shown that lower operator experience leads to increased fluoroscopy 
use (15,16). In our registry this parameter did not impact the rate of first pass PV isolation. 
Neither the patient’s anatomy or the ablation catheter type affect it, thus it seems that when 
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we perform a point-by-point radiofrequency PV isolation guided by the AI and delivering 
pulses with a short interlesion distance, the acute success is high and reproducible 
irrespective of patient and operator variables.   
Clinical use of AI. The likelihood of obtaining permanent PV isolation is related to the 
quality of ablation energy delivery and lesion formation. Catheter stability, contact force, 
power output, temperature, and duration of radiofrequency delivery are the variables that 
mainly impact lesion size and transmurality with radiofrequency energy. The AI is a novel 
marker of radiofrequency application quality that incorporates stability, contact force, time 
and power in a weighted formula, and has been shown to accurately estimate lesion depth and 
diameter in canine studies (17) and humans (18,19). Preliminary data on AF ablation guided 
by the AI have demonstrated acute durable PV isolation followed by a high single-procedure 
arrhythmia-free survival at 1 year (8-10). Significantly, in all these studies the rate of first 
pass PV isolation after a wide antral circumferential ablation was high similar and very high 
(ranging from 95 to 98%). In our multicenter study we confirmed that an ablation protocol 
respecting strict criteria for contiguity and quality lesion results in high and comparable rate 
of first pass PV isolation.   
A major concern is the AI value that should guide the ablation. From a theoretical point of 
view a higher AI value could led to a high possibility of damage of the left atrium and of the 
anatomical structure surrounding it. Das et al (18) reported that no reconnection was seen 
where the minimum AI value was ≥370 for posterior/inferior segments and ≥480 for 
anterior/roof segments. In Hussein et al (8) series AI targets were increased to 550 for 
anterior/roof and 400 for posterior/inferior left atrial segments. Taghij et al (9) used an AI ≥ 
400 at posterior wall and ≥ 550 at anterior wall. In our study we tested two AI (380 posterior-
500 anterior and 330 posterior-450 anterior) and we did not find any difference in the rate of 
fist pass PV isolations as well as in the complication rate. Although we need data on one-year 
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outcome, these prelimary results seem to support Ullah et al (19) findings that ablation 
beyond 430 AI provides minimal additional biophysical efficacy, suggesting an upper limit to 
use for clinical ablation.  
Limitations. Several limitations of our study have to be addressed. The first is that this is a 
non randomized study. No deviation from the clinical practice of each center and operator 
was required. This might justify the clinical and procedural differences in the four study 
groups. Nevertheless we believe that the reproducibility rate of the first pass PV isolation we 
observed in different patients, with different tools and operators is a strong point of our study. 
Second, although all patients underwent the same ablation protocol, some aspects, as pre-
procedural imaging, and oral anticoagulant management, were not standardized. However, 
this observational prospective study may provide a representative image of the real-life 
scenario on the use of AI module and ST and STSF catheter for AF ablation. Third, we 
evaluated the impact of the AI on reproducibility of acute PV isolation. No data are currently 
available on its impact on the mid- and long-term outcome. 
 
CONCLUSIONS 
In conclusion, an ablation protocol respecting strict criteria for contiguity and quality lesion 
resulted in high and comparable rate of acute PV isolation among operator performing 
ablation with different catheters, AI settings, procedure and fluoroscopy times. Neither the 
difference in the patients’ clinical characteristics and left atrium volume and morphology 
impacted the reproducibility of PV isolation.  
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PERSPECTIVES 
CORE CLINICAL COMPETENCIES. Outcome of atrial fibrillation catheter ablation is 
still operator dependent. This prospective, multi-center, study shows that an ablation protocol 
respecting strict criteria for contiguity and quality lesion results in high and comparable rate 
of acute PV isolation among operator with different skill performing ablation with different 
catheters, AI settings, procedure and fluoroscopy times. The difference in the patients’ 
clinical characteristics and left atrium volume and morphology did not impact the 
reproducibility of PV isolation.  
TRANSLATIONAL OUTLOOK. An AI value of 330 at posterior wall and 450 at anterior 
wall was as effective and safe as an higher one (380-500). This is a first step in identifying 
the best AI setting. 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
REFERENCES 
1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: a report of the American College of 
Cardiology/American Heart Association Task Force on PracticeGuidelines and 
the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-76. doi: 
10.1016/j.jacc.2014.03.022.  
2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management 
of atrial fibrillation developed in collaboration with EACTS. 
Europace. 2016;18:1609-1678. 
3. Sarabanda AV, Bunch TJ, Johnson SB, et al. Efficacy and safety of circumferential 
pulmonary vein isolation using a novel cryothermal balloon ablation system. J Am 
Coll Cardiol. 2005;46:1902-1912. 
4. De Filippo P, He DS, Brambilla R, Gavazzi A, Cantù F. Clinical experience with a 
single catheter for mapping and ablation of pulmonary vein ostium. J Cardiovasc 
Electrophysiol. 2009;20:367-373.  
5. Dukkipati SR, Kuck KH, Neuzil P, et al. Pulmonary vein isolation using a visually 
guided laser balloon catheter: the first 200-patient multicenter clinical experience. 
Circ Arrhythm Electrophysiol. 2013;6:467-472.  
6. Stabile G, De Ruvo E, Grimaldi M, et al. Safety and efficacy of pulmonary vein 
isolation using a circular, open-irrigated mapping and ablation catheter: A 
multicenter registry. Heart Rhythm. 2015;12:1782-1788.  
7. Arbelo E, Brugada J, Blomström-Lundqvist C, et al; on the behalf of the ESC-
EHRA Atrial Fibrillation Ablation Long-term Registry Investigators. Contemporary 
management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year 
13 
 
follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term 
registry. Eur Heart J. 2017 Jan 18. pii:ehw564. doi:10.1093/eurheartj/ehw564.  
8. Hussein A, Das M, Chaturvedi V, et al. Prospective use of Ablation index targets 
improves clinical outcomes following ablation for atrial fibrillation. J Cardiovasc 
Electrophysiol 2017;28:1037-1047.   
9. Taghij P, El Haddad M, Philips T, et al. Evaluation of a strategy aiming to enclose 
the pulmonary vein with contiguous and optimized radiofrequency lesion  in 
paroxysmal atrial fibrillation. J Am Coll Cardiol EP 2017. 
doi.org/10.1016/j.jacep.2017.06.023. 
10. Solimene F, Schillaci V, Shopova G, et al. Safety and efficacy of atrial fibrillation 
ablation guided by Ablation Index module. J Interv Card Electrophysiol. 2018 Jul 
30. doi: 10.1007/s10840-018-0420-5. 
11. Hocini M, Sanders P, Jaïs P, et al. Prevalence of pulmonary vein disconnection after 
anatomical ablation for atrial fibrillation: consequences of wide atrial encircling of 
the pulmonary veins. Eur Heart J. 2005;26:696-704. 
12. Stabile G, Di Donna P, Schillaci V, et al. Safety and efficacy of pulmonary vein 
isolation using a surround flow catheter with contact force measurement capabilities: 
A multicenter registry. J Cardiovasc Electrophysiol. 2017;28:762-767. 
13. Park CI, Lehrmann H, Keyl C, et al. Mechanisms of pulmonary vein reconnection 
after radiofrequencyablationof atrial fibrillation: the deterministic role of contact 
force and interlesiondista Cardiovasc Electrophysiol. 2014;25:701-8. 
14. Calkins H, Hindricks G, Cappato R, et al. 2017  
HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and 
surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275-e444. 
doi:10.1016/j.hrthm.2017.05.012. 
14 
 
15. Kim KP, Miller DL. Minimising radiation exposure to physicians performing 
fluoroscopically guided cardiac catheterisation procedures: a review. Radiat Prot 
Dosim. 2009;133:227–33. 
16. Pani A, Giuseppina B, Bonanno C, et al. Predictors of Zero X-Ray Ablation for 
Supraventricular Tachycardias in a Nationwide Multicenter Experience. Circ 
Arrhythm Electrophysiol. 2018 Mar;11(3):e005592. 
doi:10.1161/CIRCEP.117.005592. 
17. Nakagawa H, Ikeda A, Govari A, et al. Prospective study to test the ability to create 
RF lesion at predicted depth and diameter using a new formula incorporating contact 
force, radiofrequency power and application time (force-power-time index) in 
beating heart. [Abstract] Heart Rhythm 2014;11(Suppl):S548.  
18. Das M, Loveday JJ, Wynn GJ, et al. Ablation index, a novel marker of ablation 
lesion quality: prediction of pulmonary vein reconnection at repeat 
electrophysiology study and regional differences in target values. Europace 
2017;19:775-783.  
19. Ullah W, Hunter RJ, Finlay MC, et al. Ablation Index and Surround Flow Catheter 
Irrigation Impedance-Based Appraisal in Clinical Ablation. J Am Coll Cardiol EP 
2017;3:1080-1088. 
 
 
 
 
 
 
 
15 
 
FIGURE LEGENDS 
Figure 1. Distribution of procedure time (min) among the 12 operators that performed 
at least 15 ablation procedures. 
 
Figure 2. Distribution of fluoroscopy time (s) among the 12 operators that performed at 
least 15 ablation procedures 
 
Figure 3. Distribution of ablation time (min) among the 12 operators that performed at 
least 15 ablation procedures 
 
Figure 4. Distribution of rate of first-pass pulmonary vein isolation (%) among the 12 
operators that performed at least 15 ablation procedures 
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Table 1. Patient demographics for the total cohort of subjects, and for each study group. 
 Overall 
population 
(n=490) 
Group 
ST 330-
450 
(n=96) 
Group 
ST 380-
500 
(n=81) 
Group 
STSF 
330-450 
(n=162) 
Group 
STSF 
380-500 
(n=151) 
p 
Mean age (yrs) 59±11 58±10 59±13 60±12 59±10 0.309 
Male sex (%) 71 71 77 68 72 0.58 
BMI 27.1±4.2 27.2±3.8 28.1±4.8 27.5±4.3 26.2±4 0.018 
LA volume (ml) 104±49 95±30 134±65 114±46 79±34 <0.001 
LVEF (%) 58±8 52±10 57±7 58±8 60±7 <0.001 
Paroxysmal AF 
(%) 
80.4 81.3 75.3 79.6 83.4 0.47 
Hypertension 
(%) 
36.8 31.3 39.5 30.4 45.7 0.024 
Ischemic heart 
disease (%) 
6.3 3.7 6.2 5.3 5.5 0.88 
Valvulopathy 
(%) 
2.4 1 6.2 1.2 2.6 0.88 
Dilated 
cardiomyopathy 
(%) 
2.9 4.2 1.2 4.9 0.7 0.071 
Previous 
TIA/Stroke (%) 
2.7 1 1.2 4.3 2.6 0.44 
Diabetes 
mellitus (%) 
6.3 2.1 6.2 11.1 4 0.018 
Chronic renal 
failure (%) 
1.4 0 3.7 1.9 0.7 0.17 
NS= not significant; BMI= body mass index; LA= left atrium; LVEF= left ventricle ejection 
fraction; AF= atrial fibrillation; TIA= transient ischemic attack. 
 
 
 
 
 
 
 
 
 
17 
 
 
Table 2. Procedural data for the total cohort of subjects, and for each study group. 
 Overall 
population 
(n=490) 
Group ST 
330-450 
(n=96) 
Group ST 
380-500 
(n=81) 
Group 
STSF 330-
450 
(n=162) 
Group 
STSF 
380-500 
(n=151) 
p 
Common 
ostrium (%) 
18.4 11.5 23.5 12.3 26.5 0.002 
Accessory 
PV (%) 
5.7 2.1 3.7 6.8 7.9 0.19 
Procedure 
time (min) 
127±64 129±44 144±44 120±72 125±73 <0.001 
Fluoroscopy 
time (s) 
400±404 542±285 540±416 257±356 379±454 <0.001 
Ablation 
time (min) 
31.9±11.8 30.7±10 28.8±13.7 33.3±11.5 33±11.7 0.089 
First pass 
isolation (%) 
90±16 90±16 87±19 90±17 91±15 0.585 
Mean CF (g) 11±4 11.2±3.3 9.2±5.3 11.9±4.1 11.1±3.1 0.008 
Mean 
impedence 
drop (Ω) 
10.4±4.7 11.1±4.2 9.3±5.9 10.2±4.2 10.8±4.8 0.053 
Saline 
volume 
infusion (ml) 
974±599 1105±573 1732±664 701±287 836±503 <0.001 
NS= not significant; PV= pulmonary vein; CF= contact force.  
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